Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6502
    +0.0002 (+0.03%)
     

  • OIL

    82.74
    -0.07 (-0.08%)
     

  • GOLD

    2,328.80
    -9.60 (-0.41%)
     

  • Bitcoin AUD

    99,027.56
    -3,285.73 (-3.21%)
     

  • CMC Crypto 200

    1,388.83
    -35.27 (-2.48%)
     

  • AUD/EUR

    0.6072
    +0.0002 (+0.03%)
     

  • AUD/NZD

    1.0944
    +0.0002 (+0.02%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,121.54
    -338.54 (-0.88%)
     

Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update

Editas Medicine, Inc.
·1-min read

CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, November 8, 2021, at 8:00 a.m. ET to provide a corporate update and results for the third quarter of 2021.

To access the conference call:

  • U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.

  • Participants should ask to be connected to the Editas Medicine earnings conference call.

A live webcast and replay of the conference call can also be accessed in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.

ADVERTISEMENT

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Investors
Ron Moldaver
(617) 401-9052
ir@editasmed.com